Solon Eiendom ASA acquires, develops, and sells residential real estate properties in Norway. The company was formerly known as Bionor Pharma ASA and changed its name to Solon Eiendom ASA. The company was founded in 2006 and is based in Oslo, Norway. Solon Eiendom ASA is a subsidiary of Samhällsbyggnadsbolaget i Norden AB (publ). As on January 20, 2022, Solon Eiendom ASA was taken private.
Research context
Solon Eiendom ASA appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Real Estate
- Industry
- Real Estate - Development
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Solon Eiendom ASA is currently in a long term downtrend where the price is trading 0.2% below its 200 day moving average.
From a valuation standpoint, the stock is 62.9% cheaper than other stocks from the Real Estate sector with a price to sales ratio of 2.4.
Solon Eiendom ASA's total revenue sank by 10.3% to $292M since the same quarter in the previous year.
Its net income has dropped by 183.8% to $-42M since the same quarter in the previous year.
Finally, its free cash flow grew by 148.5% to $420M since the same quarter in the previous year.
Based on the above factors, Solon Eiendom ASA gets an overall score of 2/5.